Xylem’s New Smart Wastewater Treatment Solution Cuts Operating Costs and Reduces Energy Use by 25%
7.4.2022 15:00:00 EEST | Business Wire | Press release
Wastewater utilities can now achieve compliance targets while cutting energy consumption from aeration by up to 25% with Xylem Edge Control. This off-the-shelf suite of digital solutions for conventional activated sludge (CAS) plants marks the latest breakthrough in the digitization of water utilities. With Xylem Edge Control, wastewater operators can now control and monitor their assets, improve nutrient removal, save energy and reduce costs.
“Wastewater utilities are constantly balancing the need to ensure service reliability and compliance alongside the need to manage costs,” said Chris Taylor, Global Product Manager at Xylem. “Xylem Edge Control helps wastewater utilities confidently walk that line, bringing together our digital innovation expertise and insights from our deep bioprocessing experience, in a suite of solutions that maximizes process control while dramatically cutting energy consumption and supporting sustainability goals.”
“Utilities around the world are well on the way to digitizing their networks and reaping major water, energy and cost efficiencies. Xylem Edge Control is a versatile, multi-functional solution that meets wastewater utilities where they are on that journey – and sets them up to unlock more of the benefits of digital transformation.”
The Edge Control solutions apply analytics to real-time data to provide rapid process recommendations to optimize chemical usage and aeration. As utilities target emissions reductions, Edge Control is the latest high-efficiency technology that can help utilities cut energy-related greenhouse gas (GHG) emissions and make fast progress towards achieving net-zero targets. The platform can operate with any Programmable Logic Controller under various communications protocols and connect to existing hardware, including sensors and probes.
Xylem Edge Control combines four solutions:
- Xylem Edge Control Pulsed Aeration: A digital, energy saving solution that can prevent over-aeration of underloaded treatment plants. Pulsed Aeration improves the overall biological process of CAS plants, to provide adequate mixing and ultimately achieving energy savings. Research and implementation of Pulsed Aeration has shown energy savings of approximately 25% can be achieved.
- Xylem Edge Control Ammonia Removal: Xylem Edge Control Ammonia Removal determines a CAS facility's ammonia target and helps meet its nutrient discharge limits while working to maximize energy savings. It uses an advanced algorithm to match various load conditions, that can provide consistent ammonia removal and further stabilize the biological process.
- Xylem Edge Control Ammonia + Nitrogen Removal: The solution offers wastewater utilities the potential to save energy while reducing nitrate and ammonia concentrations. It uses an advanced algorithm which communicates with CAS facilities’ existing assets to optimize the achievement of nutrient compliance targets. Its patented, one-of-a-kind, AvN® wastewater treatment process1 has the ability to create a biological environment unlike anything the wastewater treatment industry has seen with its capacity to create a Nitrite shunt. This can allow for an expedited denitrification process and ultimately, increased energy savings. Research and implementation of Ammonia + Nitrogen Removal has shown energy savings of approximately 25% in addition to a reduction in Total Inorganic Nitrogen (TIN) concentration of approximately 30%.
- Xylem Edge Control P - Removal: This solution controls chemical feed pumps based on real-time phosphorus concentrations to reduce chemical usage while meeting today’s stricter phosphorus limits.
The launch of Xylem Edge Control follows rigorous field testing across North America, including Washington and Indiana, including the wastewater treatment operations serving the city of Muncie, Indiana.
“With Muncie being the home to Ball State University, the city undergoes a major swing in population from around 70,000 people while school is in session to approximately 48,000 when school is out of session,” said Jason Ingram, Plant Superintendent at Muncie Wastewater Treatment Plant in Muncie, IN, where Xylem Edge Control Pulsed Aeration has been installed. “That’s a decrease in population of over 30%. It is during these months of decreased load where we benefit from Pulsed Aeration most. With our upgrades from Xylem’s Pulsed Aeration we are able to save $5,000 a month on energy costs.”
Global water utilities account for approximately 2% of global GHG emissions – the equivalent of the world’s shipping industry. However, innovative solutions like Edge Control can help mitigate a substantial portion of the emissions generated by inefficient wastewater operations, quickly and affordably. Furthermore, by deploying readily available advanced solutions, utilities could cut the water industry’s GHG emissions by 50% across both clean water and wastewater activities.
Xylem Edge Control can be used as a stand-alone process or as a connected, subscription-based enterprise with fees based on efficiency and savings. When connected via the Cloud, Xylem Edge Control provides data visualization, allowing the customer to see the energy savings on a monthly basis; real-time data trending reports, showing details such as ammonia and TIN concentrations and alert and alarm texts/email notifications, displaying instrumentation and software status.
Xylem Edge Control Pulsed Aeration, Xylem Edge Control Ammonia Removal and Xylem Edge Control Ammonia + Nitrogen Removal are now available for purchase globally. Xylem Edge Control P – Removal will be available to customers globally later this year.
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our 17,000 diverse employees delivered revenue of $5.2 billion in 2021. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.
________________________
1 AvN® is a trademark of World Water Works, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005488/en/
Contact information
Media
Houston Spencer
+1.914.240.3046
Houston.Spencer@xylem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom